Evidence map›Paper›PMID 33831068›Full record

ArticlePloS one2021

Rotavirus disease burden pre-vaccine introduction in young children in Rural Southern Mozambique, an area of high HIV prevalence.

Sozinho Acácio, Tacilta Nhampossa, Llorenç Quintò, Delfino Vubil, Marcelino Garrine, Quique Bassat, Tamer Farag, Sandra Panchalingam, James P Nataro, Karen L Kotloff and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 5 countries.

Sozinho AcácioCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Tacilta NhampossaCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Llorenç QuintòCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.ORCID 0000-0001-9992-6951
Delfino VubilCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Marcelino GarrineCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Quique BassatCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Tamer FaragCenter for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, MD, United States of America.
Sandra PanchalingamCenter for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, MD, United States of America.
James P NataroCenter for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, MD, United States of America.
Karen L KotloffCenter for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, MD, United States of America.
Myron M LevineCenter for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, MD, United States of America.
Sharon M TennantCenter for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, MD, United States of America.
Pedro L AlonsoCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Inácio MandomandoCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.ORCID 0000-0002-1078-2187
Manhiça Health Research Centre · MZUniversity of Maryland, Baltimore · USInstitució Catalana de Recerca i Estudis Avançats · ESWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundRotavirus vaccines have been adopted in African countries since 2009, including Mozambique (2015). Disease burden data are needed to evaluate the impact of rotavirus vaccine. We report the burden of rotavirus-associated diarrhea in Mozambique from the Global Enteric Multicenter Study (GEMS) before vaccine introduction.

methodsA case-control study (GEMS), was conducted in Manhiça district, recruiting children aged 0-59 months with moderate-to-severe diarrhea (MSD) and less-severe-diarrhea (LSD) between December 2007 and November 2012; including 1-3 matched (age, sex and neighborhood) healthy community controls. Clinical and epidemiological data and stool samples (for laboratory investigation) were collected. Association of rotavirus with MSD or LSD was determined by conditional logistic regression and adjusted attributable fractions (AF) calculated, and risk factors for rotavirus diarrhea assessed.

resultsOverall 915 cases and 1,977 controls for MSD, and 431 cases and 430 controls for LSD were enrolled. Rotavirus positivity was 44% (217/495) for cases and 15% (160/1046) of controls, with AF = 34.9% (95% CI: 32.85-37.06) and adjusted Odds Ratio (aOR) of 6.4 p< 0.0001 in infants with MSD compared to 30% (46/155) in cases and 14% (22/154) in controls yielding AF = 18.7%, (95% CI: 12.02-25.39) and aOR = 2.8, p = 0.0011 in infants with LSD. The proportion of children with rotavirus was 32% (21/66) among HIV-positive children and 23% (128/566) among HIV-negative ones for MSD. Presence of animals in the compound (OR = 1.9; p = 0.0151) and giving stored water to the child (OR = 2.0, p = 0.0483) were risk factors for MSD; while animals in the compound (OR = 2.37, p = 0.007); not having routine access to water on a daily basis (OR = 1.53, p = 0.015) and washing hands before cooking (OR = 1.76, p = 0.0197) were risk factors for LSD.

conclusionThe implementation of vaccination against rotavirus may likely result in a significant reduction of rotavirus-associated diarrhea, suggesting the need for monitoring of vaccine impact.

Indexed as

Case-Control StudiesChildChild, PreschoolCost of IllnessFemaleHIV InfectionsHumansInfantLogistic ModelsMaleMozambiquePrevalenceRisk FactorsRotavirusRotavirus InfectionsRotavirus VaccinesRotavirus Vaccines

Identifiers

PMID33831068
PMCPMC8031087
OpenAlexW3147187936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.